Literature DB >> 30930008

Age-related differences in antibody avidities to pertussis toxin and filamentous hemagglutinin in a healthy Japanese population.

Rei Fumimoto1, Nao Otsuka2, Tomimasa Sunagawa3, Keiko Tanaka-Taya3, Hajime Kamiya3, Kazunari Kamachi4.   

Abstract

To gain insights into the current Japanese pertussis immunization schedule, we examined the distributions of antibody titers and avidities to pertussis toxin (PT) and filamentous hemagglutinin (FHA) in 460 Japanese healthy subjects (aged 1-60 years) based on age category. Our avidity enzyme-linked immunosorbent assays revealed that young children aged 1-2 years, which corresponded to ages after receiving primary and/or booster pertussis vaccinations, had relatively high-avidity anti-PT IgG (mean avidity index [AI], 40.5%) compared with other age groups (AI, 26.5-31.9%); however, they had relatively low-avidity anti-FHA IgG (AI, 41.8%). In contrast, children aged 3-6 years had both low-avidity anti-PT IgG (AI, 26.5%) and low-avidity anti-FHA IgG (AI, 40.4%). A significant age-related difference in anti-PT IgG avidity was observed between children aged 1-2 years and 3-6 years (P < 0.05); however, the difference in anti-FHA IgG avidity was not significant. The anti-PT IgG avidity was positively correlated with the antibody titer, especially among children aged 1-15 years (rs = 0.508-0.685; P < 0.01), indicating that the avidity of vaccine-induced anti-PT IgG decreases with decreasing IgG antibody titer to PT. Our findings strongly suggest that vaccine-induced anti-PT IgG avidity rapidly wanes after vaccination, but this is not observed for anti-FHA IgG avidity. Because children aged 3-6 years have both low-quantity and low-quality antibodies against PT, an additional booster vaccination with acellular pertussis vaccines is required for such children in Japan.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acellular pertussis vaccine; Antibody avidity; Antibody titer; Filamentous hemagglutinin; Pertussis; Pertussis toxin

Year:  2019        PMID: 30930008     DOI: 10.1016/j.vaccine.2019.03.055

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

1.  Seroprevalence of IgA and IgM antibodies to Bordetella pertussis in healthy Japanese donors: Assessment for the serological diagnosis of pertussis.

Authors:  Rei Fumimoto; Nao Otsuka; Hajime Kamiya; Tomimasa Sunagawa; Keiko Tanaka-Taya; Kazunari Kamachi; Keigo Shibayama
Journal:  PLoS One       Date:  2019-07-01       Impact factor: 3.240

Review 2.  Evaluation of Anti-PT Antibody Response after Pertussis Vaccination and Infection: The Importance of Both Quantity and Quality.

Authors:  Alex-Mikael Barkoff; Aapo Knuutila; Jussi Mertsola; Qiushui He
Journal:  Toxins (Basel)       Date:  2021-07-21       Impact factor: 4.546

Review 3.  Overcoming Waning Immunity in Pertussis Vaccines: Workshop of the National Institute of Allergy and Infectious Diseases.

Authors:  F Heath Damron; Mariette Barbier; Purnima Dubey; Kathryn M Edwards; Xin-Xing Gu; Nicola P Klein; Kristina Lu; Kingston H G Mills; Marcela F Pasetti; Robert C Read; Pejman Rohani; Peter Sebo; Eric T Harvill
Journal:  J Immunol       Date:  2020-08-15       Impact factor: 5.422

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.